What's in Daewon Pharmaceutical Co., Ltd.'s pipeline?

Daewon Pharmaceutical Co., Ltd. has 51 drugs in our index: 3 marketed, 0 filed, 24 in Phase 3, 1 in Phase 2, 23 in Phase 1.

Which companies overlap with Daewon Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Pfizer, Merck Sharp & Dohme LLC, Sanofi, GlaxoSmithKline, Ahn-Gook Pharmaceuticals Co.,Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daewon-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Daewon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Daewon Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 24 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 24 Phase 3 1 Phase 2 23 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Renamezin capsule	Renamezin capsule	marketed	Fluoroquinolone antibiotic	DNA gyrase, Topoisomerase IV	Infectious Disease
Telmisartan + Amlodipine	Telmisartan + Amlodipine	marketed	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels	Cardiovascular
Kremezin granule	Kremezin granule	marketed
DWKH	DWKH	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DW1026C1	DW1026C1	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DW1026S	DW1026S	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DWKH-R	DWKH-R	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
GLA5PR GLARS-NF1	GLA5PR GLARS-NF1	phase 3	Glutaminyl-tRNA synthetase inhibitor	GLARS (Glutaminyl-tRNA synthetase)	Oncology
DW1026C2	DW1026C2	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DW5421A	DW5421A	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DW1601	DW1601	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DW5121	DW5121	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Diabetes · 13
Cardiovascular · 4
Infectious Disease · 1
Musculoskeletal/Neurology (as comparator for Myonal) · 1
Oncology · 1
Pain Management · 1
unknown · 1
Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Sanofi · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 3 shared drug classes
Boryung Pharmaceutical Co., Ltd · 3 shared drug classes
Allergan · 2 shared drug classes
AJU Pharm Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Daewon Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Daewon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daewon-pharmaceutical-co-ltd. Accessed 2026-05-16.